Clinical trial
Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors
NCT00002902 · Abramson Cancer Center at Penn Medicine, Other · Completed
Key facts
| NCT number | NCT00002902 |
|---|---|
| Title | Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors |
| Official title | PHASE I TRIAL OF IRINOTECAN AND TOMUDEX IN COMBINATION ON AN EVERY THREE WEEK SCHEDULE |
| Lead sponsor | Abramson Cancer Center at Penn Medicine, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | irinotecan hydrochloride, raltitrexed |
| Start date | Apr 1, 1997 |
| First posted | May 24, 2004 |
| Last update posted | Mar 13, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: